Given the antitumor activity of CDK4/6 inhibitors on preclinical models of MPM cell lines and xenografts, a phase 2 clinical trial, MiST2, sought to test the clinical efficacy of abemaciclib in patients with p16ink4A-negative mesothelioma previously treated with platinum chemotherapy (NCT03654833). This evidence concerns the gene CDK4 and mesothelioma.